Американское общество гирудотерапии

Functional expression of a thrombin exosite I inhibitor triabin in Escherichia coli

Biochemistry study published in Biochimie (2023)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportРазработка лекарственных препаратовФармакология секрета слюнных желёзMo Z et al. · Biochimie, 2023

Abstract

Triabin, a lipocalin-like thrombin inhibitor from the saliva of the blood-sucking triatomine bug Triatoma pallidipennis, exhibits effective inhibition comparable to hirudin despite binding exclusively at exosite I. Interestingly, it was reported that higher triabin doses would not inhibit thrombin completely, which makes it a promising antithrombotic candidate agent with a larger therapeutic window. However, few structural and functional studies about triabin have been reported in the past three decades, mostly due to the lack of a reliable and practicable recombinant expression technology for this seemingly small protein. In this work, we have adopted the SUMO fusion technology for the expression of triabin in E. coli cells-with facile refolding and purification procedures-and the bioactive triabin was produced in ∼12 mg/L culture medium. Subsequently, the structure-function studies through extensive site-directed mutagenesis reveal that triabin's Phe-106 involved in the hydrophobic contacts plays a surprisingly important role in the thrombin inhibition, in contrast to the negatively charged residues Asp-135 or Glu-128 involved in the salt-bridge interaction. As such, this study complements our understanding of the interaction mechanism of natural thrombin inhibitors, which should facilitate the development of anticoagulant drugs with a novel mode of action against thrombin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsThrombinEscherichia coliSalivary Proteins and PeptidesInsect ProteinsBinding Sites

Резюме

Recombinant expression and characterization of triabin (triatomine-bug thrombin-exosite-I inhibitor) — comparative reference to leech-derived exosite-I-targeting hirudin variants.

Почему это важно для гирудотерапии

This study developed a recombinant SUMO-fusion expression system in E. coli for triabin, a thrombin exosite I inhibitor from the saliva of the triatomine bug Triatoma pallidipennis, producing ~12 mg/L of bioactive protein and using site-directed mutagenesis to show Phe-106's importance in thrombin inhibition. Triabin is noted as exhibiting effective inhibition comparable to hirudin despite a different binding mode, offering a potentially larger therapeutic window. For ASH's domain, relevance is indirect: the study concerns a non-leech hematophagous arthropod salivary inhibitor, not leeches or hirudotherapy, though the comparison to hirudin and focus on antithrombotic salivary proteins is conceptually adjacent. No leech-derived material is studied.

Цитирование

Functional expression of a thrombin exosite I inhibitor triabin in Escherichia coli.

Mo Z et al. · Biochimie, 2023

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.